Neuroblastoma Companies

Latest Neuroblastoma Companies Updates:

Jan 2024

Bluebird bio,Received FDA Fast Track designation for their CAR-T cell therapy, bb281, for treating high-risk relapsed/refractory neuroblastoma.Partnered with leading children's hospitals to establish clinical trial networks and expand access to their CAR-T therapy for young neuroblastoma patients.

Aptevo Therapeutics Announced positive Phase 1 data demonstrating the safety and preliminary efficacy of their novel small molecule drug, APG-115, for treating relapsed/refractory neuroblastoma.Initiated Phase 2 clinical trials evaluating APG-115 in combination with standard chemotherapy for high-risk neuroblastoma patients.

Immunomedics,Received orphan drug designation from the FDA for their radiopharmaceutical therapy, 131I-metaiodobenzylguanidine (MIBG), for treating high-risk neuroblastoma.Collaborated with healthcare providers to optimize the use of MIBG therapy and improve treatment outcomes for neuroblastoma patients.

Kyushu University (Japan) Launched a clinical trial evaluating the safety and efficacy of GAIA-102, a novel anti-GD2 antibody-drug conjugate, for treating refractory/relapsed neuroblastoma or pediatric solid tumors with lung metastases.Focused on developing innovative therapeutic options specifically targeting high-risk and aggressive forms of neuroblastoma.

Children's Oncology Group (COG) (US) Launched a new clinical trial comparing two different chemotherapy regimens for treating high-risk infants with neuroblastoma.Continued research efforts to identify optimal treatment strategies and improve survival rates for neuroblastoma patients across different age groups and risk categories.

List of Neuroblastoma Key companies in the market

• Lonza Biologics Ltd PerkinElmer Inc.


• BD Biosciences


• bioMerieux


• Beckman Coulter Inc.


• GE healthcare


• EMD Chemicals Inc. Meridian Life science Inc.


• Shimadzu Biotech


• Takara Bio Inc.